Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

This activity was originally broadcast in conjunction with AMCP 2024.

Program Description

Therapeutic developments in the treatment of chronic lymphocytic leukemia (CLL) have identified mechanisms for Bruton tyrosine kinase (BTK) inhibition that have shown to improve survival and quality of life outcomes for patients. Both covalent and noncovalent BTK inhibitors have been included in national treatment guidelines for patients with CLL, necessitating that pharmacists and managed care professionals understand the utility of these agents. This program will explore challenges in the treatment of patients with CLL, including development of resistance and treatment sequencing. Faculty experts will discuss updates to the growing body of evidence for the use of targeted therapy combinations and the emerging use of noncovalent BTK inhibitors within the treatment paradigm. Considerations for managed care professionals and pharmacists to assess adverse effects, disease progression, and the economic burden of indefinite treatment for patients with CLL will also be presented.

Target audience: Managed care and oncology pharmacists

Type of activity: Application
Release date: May 1, 2024
Expiration date: July 1, 2025

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Break down the current evidence-based treatment approach for the use of small-molecule inhibitors in the management of chronic lymphocytic leukemia (CLL).
• Analyze the real-world evidence and emerging trends to address the challenges in the treatment of patients with CLL.
• Explore managed care strategies in mitigating the risk of major toxicities associated with small-molecule inhibitors in CLL.
• Identify the managed care considerations on the evolving treatment paradigm for patients with CLL to optimize adherence and patient outcomes.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-129-H01-P. The activity is available for CE credit through May 3, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Alison Duffy, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: BeiGene Advisory Board

Speakers Bureau: Amgen

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Timothy Y. Mok, PharmD, BCOP, BCPS

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Daphne Davis, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:

Former employee: GSK

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms